Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Provided By GlobeNewswire
Last update: Aug 5, 2025
– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors –
– First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant
MTA-cooperative PRMT5 inhibitor in development for glioblastoma –
NASDAQ:TNGX (10/10/2025, 9:47:11 AM)
7.425
+0.1 (+1.43%)
Find more stocks in the Stock Screener
